Labcorp Holdings Inc. (LH) key performance indicators and operating metrics (19 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Revenue (total) | 3.54B | FY2026-Q1 |
| Biopharma Laboratory Services Revenues, as Reported | 780.8M | FY2026-Q1 |
| Diagnostics Laboratories Revenues, as Reported | 2.76B | FY2026-Q1 |
| Adjusted earnings per share | 4.25 USD_per_share | FY2026-Q1 |
| Backlog (BLS) | 8.64B | FY2026-Q1 |
| Free cash flow (Free Cash Flow) | 70.5M | FY2026-Q1 |
| TTM Book to Bill | 1.04 ratio | FY2026-Q1 |
| TTM Net Orders | 3.29B | FY2026-Q1 |
| Depreciation | 94M | FY2026-Q1 |
| Total Adjusted EBITDA | 601.9M | FY2026-Q1 |
| Total Debt to Last Twelve Months Adjusted EBITDA | 2.60 ratio | FY2026-Q1 |
| Total Net Debt to Last Twelve Months Adjusted EBITDA | 2.20 ratio | FY2026-Q1 |
| Amortization of Intangibles and Other Assets | 75.6M | FY2026-Q1 |
| Biopharma Laboratory Services revenue (total) | 793M | FY2025-Q4 |
Back to LH overview · LH earnings · LH holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.